Profit Warnings, Insulin Settlements, and Leqembi

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, health economist, and it's great to have you with us today.

SaraAnd I'm Sara, market access strategy. Always good to be here — and I'll say, I've had today's topics circled since this morning. The healthcare system turbulence is palpable right now.

MarcusSame here. We're looking at HCA's profit warning and its implications for US healthcare access — that's a seismic shift in hospital system economics. Then the FTC settlement with CVS Caremark over insulin pricing — a major policy enforcement move. Plus the subcutaneous Leqembi approval and what that means for Alzheimer's evidence strategies. And ICER expanding scientific advice services — that's reshaping early evidence development.

SaraThat second one is particularly interesting to me — the insulin pricing settlement could set precedents for how antitrust enforcement interacts with formulary access decisions.

MarcusExactly. Let's get into it.

MarcusStarting with HCA's profit warning — this isn't just one hospital system struggling. We're seeing major for-profit hospital groups flagging financial pressures, which suggests broader structural issues in US hospital economics. What's striking here is how this directly impacts access to care, especially for high-cost therapies administered in hospital settings.

SaraThat's one read — but from a payer perspective, I'm wondering if this signals a fundamental shift in cost-shaping dynamics. If hospitals are losing money, they may become more aggressive in negotiating drug contracts or restricting access to high-margin therapies. The budget impact question there is one the field hasn't fully worked out yet.

MarcusThat connects to something I keep coming back to: the financial sustainability of healthcare delivery systems. When hospital margins tighten, the pressure cascades to pharmaceutical pricing. We've seen this in Europe with hospital payment systems, but the US model is different. The part that gives me pause is how this affects evidence generation for drugs used in outpatient settings that get pulled into inpatient administration.

SaraRight, and from the payer side, this creates a perverse incentive. If hospitals are losing money, they might push for higher drug margins to compensate, which then increases overall system costs. That's a classic access paradox.

MarcusI'd push back slightly on that framing. The data suggests HCA's issues are more about underinsurance and uncompensated care than drug pricing specifically. But your point about cost-shaping is valid — we need to watch how this influences formulary negotiations for injectables and biologics.

SaraThat's fair, though I think payers would see it differently. The immediate concern is whether this accelerates hospital consolidation, which could further concentrate pricing power. What we're seeing in Texas might be a bellwether for national trends.

MarcusAgreed. The operationalization of this will be critical. Moving on to the FTC settlement with CVS Caremark over insulin pricing — this is a significant enforcement action against a PBM for allegedly inflating insulin costs through spread pricing and other practices.

SaraWhat strikes me about that is the timing. Coming right after the insulin cap implementation, this suggests the FTC is taking a more aggressive stance on PBM practices. But I wonder if that's the full picture though — the settlement terms haven't been fully disclosed, and we don't know how this will actually impact patient out-of-pocket costs versus rebates.

MarcusThat's a crucial point. The enforcement signal is clear, but the operational impact remains ambiguous. Historically, PBM settlements often result in minimal consumer benefit. The methodology here is interesting — the FTC is using consumer protection statutes rather than antitrust, which could set different precedents.

SaraExactly. And what this means for market access teams is that the insulin pricing landscape is becoming more fragmented. We now have federal price caps, state-level insulin programs, and now PBM enforcement. The budget impact calculations just got exponentially more complex.

MarcusI keep coming back to the opportunity cost angle. If PBMs are forced to reduce spread pricing, where does that margin go? Does it flow to patients, manufacturers, or disappear? The evidence isn't clear yet, but this could reshape commercial strategies for insulin manufacturers.

SaraThat's one of those stories where the details matter more than the headlines. We'll need to see the actual settlement terms to understand the real-world implications. The payer community will be watching this closely as a potential template for other therapeutic areas.

MarcusMoving to the subcutaneous Leqembi approval — this is the first subcutaneous formulation for an Alzheimer's therapy, which changes administration paradigms. What's interesting here is how this affects the evidence generation landscape. Subcutaneous administration could improve adherence but may alter the risk-benefit profile.

SaraThat's fair, though I think payers would see it differently. The key question is whether this new formulation will be positioned as a value add or a cost increase. If it requires more frequent dosing or has different adverse event profiles, the cost-effectiveness calculations shift significantly. The HEOR evidence will need to capture both clinical and economic impacts.

MarcusI'd frame it slightly differently — this is about expanding treatment options. The IV formulation had significant access barriers due to administration complexity. A subcutaneous option could address some of those, but we need to see the comparative effectiveness data. The part that gives me pause is whether this will be approved as a new indication or reformulation, which affects pricing strategy.

SaraWhat we're seeing with Alzheimer's drugs is that payers are increasingly demanding real-world evidence alongside clinical data. This new formulation might generate different safety signals, and RWE will be critical to understanding long-term outcomes. The budget impact could be substantial if uptake increases due to easier administration.

MarcusThat connects to the broader trend of route-of-administration innovations. We saw this with CAR-T therapies moving from inpatient to outpatient settings. The operationalization challenge is significant — will this require new provider networks or training programs? Those are often hidden costs in value assessments.

SaraRight, and from a payer perspective, the question is whether this reduces overall system costs by enabling home administration or increases them through different utilization patterns. The evidence will need to capture both direct and indirect costs. This is one of those stories where the implementation details will determine success.

MarcusFinally, ICER expanding scientific advice services — they're now offering more comprehensive early evidence development support, including real-world data planning and health economic modeling. This is a significant shift in how companies approach value demonstration.

SaraWhat strikes me about that is the timing. With the IRA implementation accelerating, having early clarity on evidence requirements is becoming more critical. But I wonder if that's the full picture though — ICER's expansion might create a two-tier system where companies that engage early have advantages, potentially exacerbating access disparities for smaller players.

MarcusThat's a thoughtful counterpoint. The methodological rigor here is important — ICER is emphasizing adaptive trial designs and RWE integration, which could improve evidence quality. But your point about market access equity is valid. This could create a barrier to entry for smaller biotechs that lack the resources for extensive early engagement.

SaraExactly. And what this means for evidence strategy teams is that the cost of evidence generation might increase. The budget impact question is whether these expanded services will lead to more efficient submissions or just add another layer of complexity. The payer community will need to balance thoroughness with practicality.

MarcusI keep coming back to the innovation incentive angle. If early scientific advice reduces uncertainty, it might encourage more investment in high-risk, high-reward therapies. The part that gives me pause is whether ICER's expanded role overlaps with FDA regulatory processes, creating potential conflicts or redundancies.

SaraThat's one of those stories where the proof will be in the pudding. We'll need to see how these expanded services are received by both industry and HTA bodies. The key will be whether this leads to more timely access decisions or just adds another step in the process.

SaraA lot to think about today. I'll be watching how the HCA profit warning impacts hospital negotiations for high-cost therapies, especially as we head into the second half of the year.

MarcusSame — and for me the thread running through today is the increasing complexity of US healthcare economics. From hospital finances to insulin pricing to Alzheimer's administration, every decision creates ripple effects that access teams must navigate.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.